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The in vitro and in vivo efficiency of fibroin microparticles as a delivery carrier for bone morphogenetic protein-2
(BMP-2) was evaluated. BMP-2 was encapsulated in silk fibroin particles that were produced by a simple and very
mild processing method. The dose–response of BMP-2-loaded fibroin particles was examined in C2C12 cells, after
5 days of culture. The BMP-2 retained most of its activity as observed by the increase in alkaline phosphatase
activity, which was much higher when BMP-2 was encapsulated into the particles rather than just surface-
adsorbed. After 2 weeks of culture, increased mineralization was observed with BMP-2-loaded particles in
comparison to soluble added growth factor. No significant cytotoxicity was detected. When implanted in a rat
ectopic model, bone formation was observed by in vivo micro-computed tomography after 2 and 4 weeks post-
implantation, with particles loaded with 5 or 12.5 mg BMP-2. An increase in bone density was observed over time.
Histology revealed further evidence of ectopic bone formation, observed by strong alizarin red staining and
osteocalcin immunostaining. Our findings show that fibroin microparticles may present an interesting option for
future clinical applications in the bone tissue engineering field, and therefore, further studies have been planned.
Introduction
Bone morphogenetic proteins (BMPs) are a group ofcytokines from the transforming growth factor-beta
(TGF-b) superfamily, which have been used as powerful
osteoinductive components in several late-stage tissue engi-
neering products for bone grafting.1–3 Currently, two devices
using BMPs have been approved by the Food and Drug
Administration for human clinical application based on the
use of collagen sponges.4 However, as collagen poses several
drawbacks such as suboptimal handling conditions and the
risk of disease transmission, there is still a need for an opti-
mized BMP delivery system.
The search for efficient, simple, and cheap delivery sys-
tems for drug targeting has lead to a great investment in
the area of nano- and microparticles for drug delivery. In
tissue engineering, these systems are excellent choices for
growth factor delivery, because they can be easily prepared
and sterilized. They can be processed into injectable sys-
tems allowing an easy and noninvasive implantation in the
patient.5
Diverse synthetic and natural origin polymers have been
suggested as alternatives for the delivery of BMPs in bone
tissue engineering.3,6 Silk fibroin offers a versatile option as a
natural biocompatible and biodegradable protein polymer
that has been shown to efficiently deliver BMPs in a variety
of works.7–10 Recently, a simple method for producing
fibroin microparticles was described,11–13 and these micro-
particles were explored as a potential new carrier for the
encapsulation and sustained release of different BMPs.14 In
this study, we examined the activity of BMP-2 released from
fibroin microparticles in vitro in C2C12 cells, by quantifica-
tion of the alkaline phosphatase (ALP) activity and calcium
mineralization, and in a rat ectopic bone formation model,
using microcomputed tomography (mCT) and histological
analysis.
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Materials and Methods
Materials
Silk-containing Bombyx mori cocoons were purchased
from Halcyon Yarn (Bath, ME). The silk fibroin was isolated
from the cocoons, following an adapted degumming proto-
col.12 Fibroin microparticles were prepared using the method
of Cao and colleagues,13 with modifications. Briefly, a solu-
tion of 1% (w=v) fibroin in phosphate-buffered saline was
prepared, to which 0.5 mg BMP-2 (Wyeth, Maidenhead,
United Kingdom) was loaded, per mg of fibroin. This solution
was incubated at room temperature with stirring (600 rpm),
while absolute ethanol was added dropwise at a ratio of 1:2 to
the initial volume of fibroin. The solution was incubated
overnight at!208C, washed with distilled water, collected by
centrifugation, and freeze-dried. The characterization of the
fibroin microparticles by scanning electron microscopy, dy-
namic light scattering, and swelling behavior and the release
profile of BMP-2 have been described elsewhere.14 The re-
sulting particles had an average diameter of 2.7þ 0.3 mm. All
other chemicals were of analytical grade.
Methods
Bioactivity in C2C12 cells. C2C12 cells have been used
for screening the osteogenic activity of BMPs in a variety of
works.15–18 These cells do not express significant amounts of
endogenous BMPs, thus making them an effective model for
testing the activity of the released BMP-2.19 C2C12 cells were
seeded at 105 cells=mL per well in a 24-well plate, attached in
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 1% (v=v) fetal calf serum, at 378C and 5% CO2,
in a humidified environment. The cells were incubated with
unloaded particles or with particles containing 0.1, 0.5, 1.0, or
2.5 mg encapsulated BMP-2 (Wyeth). BMP-2 was added as a
positive control to the culture medium at 0.1, 0.5, 1.0, or
2.5 mg=mL. As another control, unloaded particles that were
immersed for 30min in 5 mg=mL BMP-2 and washed twice
were also added to the cells (adsorbed BMP control); these
particles were added in the same volumes as the particles
with encapsulated growth factor were added to the cultures.
ALP enzymatic activity was measured according to standard
procedures,20 after 5 days in C2C12 cultures. The activity
recovery of the encapsulated BMP-2 was estimated by
comparing the ALP activity induced by a specific amount of
growth factor released from the fibroin particles14 to the ac-
tivity induced by the same amount of growth factor added to
the culture medium as a positive control.
Alizarin red mineralization. For the alizarin red mineral-
ization assay, C2C12 cells were seeded at 3#104 cells=mL per
well and cultured in DMEM supplemented with 100mM
ascorbic acid and 10mM b-glycerophosphate, in the presence
of both unloaded and BMP-2-loaded (0.5 mg) microparticles.
BMP-2 was also added as a control at 0.5 mg=mL to the cul-
ture media. Media and particles were replaced every 5 days.
After 14 days of culture, the cells were washed for three
times with phosphate-buffered saline (without Ca2þ, Mg2þ)
and fixed in 4% (v=v) formaldehyde for 30min. After re-
moval of the fixative, cells were washed twice with distilled
water and covered with alizarin red 1% solution, followed by
gentle agitation in an orbital shaker for 10min. The solution
was then removed and the cells were washed three more
times with distilled water. The cells were observed using a
Axiovert10 (Zeiss, Jena, Germany) optical microscope and
imaged with a coupled Coolpix950 (Nikon, Tokyo, Japan)
camera. The mineralization was quantified by the method
proposed by Gregory et al.21 Briefly, the calcium from cells
was extracted by adding 800 mL acetic acid (10%, v=v) to each
well and incubating for 30min in an orbital shaker. Then the
suspensions were transferred to a clean 1.5mL Eppendorf
tube and vortexed for 30 s; 500 mL of mineral oil was added
and the suspensions were heated to 858C for 10min and then
cooled in ice for 5min. The suspensions were centrifuged
(20min, 10,000 g), the supernatant carefully removed, and
200 mL ammonium hydroxide (10%) was added (until pH
*4.1). The solutions were read for absorbance at 405 nm in a
Spectra III spectrophotometer (SLT, Salzburg, Austria).
Cell viability assay. Human osteosarcoma cell line (SaOS-
2 cell line; European collection of cell cultures (ECACC) was
used for cell viability tests instead of murine C2C12 cell line,
because it is a well-established human cell line of an osteoblast
phenotype. Human osteosarcoma cells were seeded at 106
cells=mL in a 24-well plate, attached overnight in DMEM
with 1% fetal calf serum and no antibiotics, at 378C and 5%
CO2, in a humidified environment, and cultured for 1, 3, and 5
days. Unloaded fibroin particles were added to the cell cul-
ture at 0.5mg=mL. 3-(4,5)-dimethylthiazol-2-yl)-5-(3-carboxy-
methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt (MTS)
cell viability assay was determined after these time periods,
using a standard procedure.20 Latex rubber (Velos-Perforex,
Manchester, United Kingdom) and standard culture medium
were used as positive and negative controls, respectively.
Latex rubber is known to have a strong cytotoxic effect lead-
ing to extensive cell death and lysis and is commonly used as a
positive control for cell death. All the samples were tested in
triplicate for at least two independent experiments with re-
producible results. The results are expressed as a percentage
of the control (scored as 100% viability) as mean$ standard
deviation.
Rat ectopic bone formation model. Male Sprague–
Dawley rats (weighing 340–360 g) were purchased from
the Institut fu¨r Labortiertechnik und -genetik (Himberg,
Austria). The rats were housed in light- and temperature-
controlled facilities and given food and water ad libitum. In
three animals, surgery was performed after general anes-
thesia with an intramuscular injection of 60mg=kg of body
weight (BW) ketamine (Ketavet!; Pharmacia, Erlangen,
Germany) and 7.5mg=kg BW xylazine (Rompun!; Bayer,
Leverkusen, Germany). After shaving and disinfecting the
dorsum of the animals, four midsagittal incisions were made
dorsally in the proximal area of each limb and subcutaneous
pockets were created by blunt dissection. The fibroin parti-
cles were implanted subcutaneously into each pocket. Three
groups were defined as follows: Group I (unloaded parti-
cles), Group II (particlesþ 5mg BMP-2), and Group III (par-
ticlesþ 12.5 mg BMP-2). The animals were randomized and
were implanted with four samples (n¼ 4) per each group.
Only one group was assigned to each animal to avoid the
potential interference of released BMP by blood circulation.
After placement of the particles, the incisions were closed
with sutures, and the wound was covered with vapor-
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permeable spray dressing (Opsite!; Smith & Nephew,
London, United Kingdom). Analgesia treatment was given
postoperation, with 0.01mg=kg BW Buprenorphin. At the
end of each implantation period (4 weeks), the animals were
sacrificed and samples from the tissues surrounding the
implantation site were harvested. The animal protocol was
approved by the authority of the city government of Vienna.
Microcomputed tomography. Live mCT (vivaCT 75;
Scanco Medical AG, Bru¨ttisellen, Switzerland) was used to
examine ectopic bone formation in individual rats. mCT im-
aging was performed at weeks 2 and 4. The animals were
anesthetized for 5min with 2% isoflurane during measure-
ment, and the dorsal regions in proximity to the limbs were
examined. No X-ray contrast media were used in this study.
Image reconstruction was performed using the built-in three-
dimensional visualization software (Scanco Medical AG).
The evaluation of newly formed bone and bone density was
performed using IPL version v5.06b (Scanco Medical AG).
Histology. Harvested samples were fixed in neutral
buffered 10% formalin and embedded in paraffin. Three-
micrometer or 4-mm sections were cut and stained with
hematoxylin and eosin (H&E) or alizarin red S, respectively,
for light microscopy observation. For a detailed analysis of
tissue differentiation, immunohistochemical staining was
performed in selected samples. Briefly, paraffin sections were
dewaxed with xylene and rehydrated in a graded ethanol
series. After enzymatic antigen retrieval with 0.1% protein-
ase (Sigma Aldrich, St. Louis, MO), sections were incubated
with an osteocalcin antibody (Santa Cruz Biotechnology,
Santa Cruz, CA) in a humidified chamber at 48C overnight.
After rinsing, sections were incubated with the EnVision"
system (Dako, Glostrup, Denmark) at room temperature for
30min and immunoreactivity was visualized with 3-amino-
9-ethylcarbazole (AEC) chromogen solution (Thermo Fisher
Scientific, Hudson, NH). Slides known to express osteocalcin
were used as positive controls, and those without the pri-
mary antibody served as negative controls.
Statistical analysis. Experiments were performed in
triplicate and expressed as means$ standard deviation, un-
less stated otherwise. Student’s t-test was used for statistical
analysis using a two-tailed nonpaired test. Statistical signif-
icance was defined as p< 0.05 for a 95% confidence, and
p< 0.01 for a 99% confidence.
FIG. 1. Alkaline phospha-
tase (ALP) activity of C2C12
cells after 5 days of culture.
A–D: Particles were added in
similar amounts to the cell
cultures containing encapsu-
lated BMP-2 (0.1, 0.5, 1.0, or
2.5 mg, respectively), ad-
sorbed BMP-2, or no growth
factor (unloaded particles).
Controls were obtained from
cells incubated only with 0.0,
0.1, 0.5, 1.0, or 2.5 mg=mL
BMP-2. ALP activity is re-
ported as nmol=min=mg of
total protein (mean$
standard deviation, n¼ 3).
Statistical differences indi-
cated (*p< 0.01) are relative to the negative control without growth factor or particles. BMP-2, bone morphogenetic protein-2.
Color images available online at www.liebertonline.com=ten.
FIG. 2. Alizarin red mineralization staining showing sites of calcium phosphate deposits (orange color) in C2C12 cell line
differentiated into osteoblast after 14 days of culture with particles loaded with 0.5 mg BMP-2 (A), and 0.5 mg=mL BMP-2
added to culture medium (B). Unloaded fibroin particles did not show any mineralization (C). Color images available online
at www.liebertonline.com=ten.
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Results
ALP and osteogenic mineralization in C2C12 cells
The bioactivity of BMP-2 released from the silk fibroin
microparticles was studied by determining the ability to in-
duce ALP enzymatic activity over basal levels in C2C12 cells
(negative controls) after 5 days of culture, and by comparing
the cell response to a BMP-2 dose–response effect directly
added to the culture medium (positive control). The BMP-2
released from the fibroin particles was able to induce a
significant increase in the ALP activity over basal levels
after 5 days ( p< 0.01; Fig. 1). The remaining activity of
encapsulated and released BMP-2 was estimated as 88.9%$
6.1%. At this period, 76.9%$ 6.4% of loaded BMP-2 were
released from the particles, as calculated elsewhere.14 Cells
were observed to differentiate into osteoblast morphology
(data not shown). The fibroin particles with only adsorbed
BMP-2 were able to induce solely a small increase, but sig-
nificant ( p< 0.01), in ALP activity. Unloaded particles did
not induce any increase in ALP activity or osteoblast mor-
phology. After 2 weeks of cell culture, the BMP-2-loaded
particles were able to induce mineralization as observed by
alizarin red staining (Fig. 2). No mineralization was observed
for cells cultured with unloaded particles. The amount of
calcium was significantly higher ( p< 0.01) for fibroin parti-
cles loaded with BMP-2 (1897.7%$ 16.0%) compared with a
FIG. 3. Cell viability tetrazolium salt 3-(4,5)-dimethylthiazol-
2-yl)-5-(3-carboxy-methoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium salt (MTS) test performed in SaOS-2 cells as a
function of the time of cell culture with 0.5mg=mL silk
fibroin microparticles. Dulbecco’s modified Eagle’s medium
(DMEM) and latex were used as a negative and a positive
control for cell death, respectively (mean$ standard deviation,
n¼ 3). Color images available online at www.liebertonline
.com=ten.
FIG. 4. mCT images of ec-
topic bone formation (see in-
sets) induced by unloaded
fibroin particles after 4 weeks
(A), fibroin particlesþ 5 mg
BMP-2 after 4 weeks (B), and
fibroin particlesþ 12.5 mg
BMP-2 after 2 weeks (C) and
after 4 weeks (D). Scale bars:
5mm. mCT, microcomputed
tomography. Color images
available online at www
.liebertonline.com=ten.
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corresponding dose of BMP-2 added to media as a standard
positive control (899.4%$ 11.3%).
Cell viability
The silk fibroin microparticles did not show any signifi-
cant evidence of cytotoxicity in human osteosarcoma cells,
after 1, 3, or 5 days of cell culture (Fig. 3). The cells were able
to proliferate normally during this time period. MTS is a
viability=proliferation test, and an inverse relationship of
toxicity to cells can be assumed.20 Data correlated with the
morphological observations of the cells by optical micros-
copy (data not shown). Similar data were also obtained when
particles were tested in primary cultures of human adult
adipose-derived stem cells (data not shown).
In vivo mCT
All animals showed no complications in wound healing,
during the 4-week follow-up. After 2 and 4 weeks, all sites of
fibroin particle implantation were easily identified and re-
trieved for analysis. The mCT reconstructions (Figs. 4 and 5)
clearly showed ectopic calcifications in sites where BMP-2-
loaded particles (Groups II and III) were implanted. In
Group II (fibroin particlesþ 5 mg BMP-2), no ectopic bone
could be detected after 2 weeks, possibly because it was
below the threshold of sensitivity of the mCT equipment.
However, at week 4, ectopic bone was clearly visible having
a bone volume of 2.5$ 0.5mm3 and 288.2$ 20.8mg hy-
droxyapatite (HA)=mm3 (mineral density). In Group III
(fibroin particlesþ 12.5 mg BMP-2), ectopic bone formation
was observed at both weeks 2 and 4 postimplantation.
Comparing the mCT reconstructions in this group, there was
an increase in both the bone volume and bone density
(1.9$ 0.6 to 2.3$ 0.9mm3 and 178.3$ 11.3 to 353.0$ 88.0mg
HA=mm3; p< 0.05; Fig. 6). The dimensions of the newly
formed bone were nearly similar between the two time pe-
riods, which varied from 1 to 3mm in width. At week 2, the
structure of bone was rather indistinct; however, at week 4,
the bone formed as a solid shell on part of the surface and
had a trabecular structure inside. In the control group
(Group I, unloaded fibroin particles), no ectopic bone for-
mation could be detected.
FIG. 5. Detailed mCT images
of ectopic bone formation in-
duced by fibroin parti-
clesþ 12.5 mg BMP-2 after 2
weeks (A, B) and 4 weeks
(E, F), and fibroin parti-
clesþ 5mg BMP-2 after 4
weeks (C, D). Background
signal in A and B is due to a
lower threshold used for
imaging. Scale bars: 1mm.
FIBROIN MICROPARTICLES FOR DELIVERY OF BMP-2 941
Histology
H&E staining revealed no signs of vascularization, but in
Group II some parts showed calcified tissue. In this group,
H&E staining revealed abundant presence of osteoblasts
and osteocytes surrounded by an extracellular matrix (Fig.
7A). These tissues showed intense alizarin red staining (Fig.
7B). In Group III, no alizarin red-positive areas could be
observed, despite the fact that in the mCT, ectopic bone
formation was observed. At the time of harvest it was not
possible to localize where the new bone formation was
occurring. No staining was detected in the control group as
expected (data not shown). Immunohistological evaluation
with an osteocalcin-specific antibody revealed moderate
staining in sections of Group II (Fig. 7C), in the site where
osteoblasts surrounding a mineralized matrix were de-
tected. Staining was not detected in a negative control with
no incubation with the osteocalcin antibody (data not
shown).
Discussion
The need for an efficient delivery system for BMPs as a
way of providing effective and sustained stimulation of bone
formation, as shown in several experimental models,22 has
been well recognized. The main role of a carrier is to retain
these growth factors at the site of injury for a prolonged time
frame, protecting the immobilized drugs from degradation
and maintaining its bioactivity, while releasing the protein in
a time- and site-controlled way to promote the formation of
new bone at the treatment site.
Silk fibroin biomaterials have been explored as novel
alternatives for drug delivery and in tissue engineering, as a
result of their biocompatibility, biodegradability, mechani-
cal strength, and versatility of formats into which the ma-
terial could be processed.23 In this study we examined the
in vitro and in vivo delivery of BMP-2 from fibroin micro-
particles.
The basis for evaluating the activity of the BMP released
by the fibroin particles was to test initially the particles loa-
ded with growth factor in C2C12 cell line and then using a
FIG. 7. Hematoxylin and eosin staining for animals im-
planted with fibroin particlesþ 5 mg BMP-2 at 4 weeks after
implantation (A). Newly formed bone was indicated by the
presence of a mineralized extracellular matrix (E.M.) stained
with alizarin red (B), osteocytes (O.C.), and osteoblasts (O.B.)
stained by osteocalcin immunostaining (C). Color images
available online at www.liebertonline.com=ten.
FIG. 6. Bone density (mg hydroxyapatite=mm3) and bone
volume (mm3) of ectopic bone evaluated by mCT. Fibroin
particlesþ 5mg BMP-2 (II); fibroin particlesþ 12.5 mg BMP-2
(III). Error bars reflect standard error. *No ectopic bone was
detected. **Significant ( p< 0.05) difference between each other.
Color images available online at www.liebertonline.com=ten.
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rat ectopic bone formation model. C2C12 murine pre-
myoblast cells are well defined by their ability to rapidly
differentiate into osteoblasts when cultured in the presence
of BMPs.15,16,24 In these cells, fibroin particles loaded with
BMP-2 were able to induce a significant increase in ALP
activity (after 5 days of culture), osteoblast-like morphology,
and the formation of a mineralized matrix (after 2 weeks of
culture), thereby confirming that the growth factor was loa-
ded into the particles, retaining its bioactive state. This adds
value to the method formerly developed to produce fibroin
particles by ethanol precipitation,11–13 confirming that it re-
tains the activity of encapsulated drugs. Similar cases were
reported but using different methodologies. In one report,
fibroin particles retained the activity of loaded horseradish
peroxidase, using lipid vesicles as particle templates, fol-
lowed by methanol treatment,25 whereas in another work,
silk spheres, produced by nozzle vibration and methanol
treatment, retained the activity of insulin growth factor-1.26
In contrast, the method herein described is more simple, and
its milder processing steps may allow the encapsulation of
growth factors while retaining most of their activity. In our
study, the activity recovery was estimated as 88.9%$ 6.1%,
whereas no such results were presented in the former works
using silk particles as carriers for BMP-2 delivery.
As particles with surface-adsorbed BMP-2 induced only
low levels of ALP, it is likely that most of the growth fac-
tor accountable for the significant increase in ALP levels is
BMP-2 encapsulated into the particles during their fabrica-
tion. This adds support to our previous report that BMP-2 is
released in a sustained way for a period of up to 2 weeks.14
This is also confirmed by the increased mineralization, over
the same period, induced by particles containing the BMP-2,
when compared with the corresponding doses of growth
factor added to the culture media. No cytotoxicity was de-
tected by the use of fibroin particles in vitro, as inferred by
the MTS cell viability assay. In general, silk fibroin has been
regarded as a good biocompatible material, effecting low
immune responses in vivo, and with an historical use as su-
tures in clinical applications.27–29 This adds further evidence
that these materials could be used as a viable option for
future clinical applications.
Ectopic bone formation models in rodents have been used
to test the activity of BMPs in a wide variety of studies.30–34
The microparticles could form a slurry, which was easily
implanted ectopically in rats. After 2 and 4 weeks, bone for-
mation was observed in all sites of implantation of BMP-2-
loaded particles and the extent of ectopically formed bonewas
measured by mCT. Mineralized areas of bone were found as
early as after 2 weeks postimplantation and increased in both
bone volume and HA density after 4 weeks. Live mCT is a
reliable and noninvasive method for scanning and evaluation
along time of bone mass, structure, geometric, and density
parameters.35 The use of mCT imaging maximizes the results
from single animals, offering sequential data within the same
animal, thus reducing this way the required number of ani-
mals per study.36 Ectopic bone formation was also confirmed
by histological analysis performed at 4 weeks postimplanta-
tion. New bone formation was detected by the presence of a
calcified extracellular matrix, which was stained by alizarin
red, revealing only surface mineralization without quantita-
tive data, when compared with the mCT data. In addition,
osteocalcin, a calcium-binding protein and amarker ofmature
bone formation,37 was also detected in the cells surrounding
the newly formed bone.
New bone formation occurs as released BMP-2 triggers
the recruitment of stem cells that differentiate into osteo-
blasts and form a calcium phosphate matrix.38 This can only
occur if there is not only an initial stimulation of the site by
BMP-2, but also a sustained released of the growth factor in
the following weeks, allowing the formation of new bone.
In the lack of a sustained release, the BMP-2 is usually
cleared from the implant site within hours, supposedly
terminating its local effect.39 This is demonstrated by
studies where surface-adsorbed BMP-2 was used in the
particles that failed to induce new bone formation probably
because of either loss of the BMP bioactivity or insufficient
duration of stimulus.40 In fact, we have observed the same
lack of activity in our in vitro data for particles with ad-
sorbed BMP. In one report, TGF-b2, another member of the
TGF-b superfamily, completely lost activity after 1 week of
incubation at 378C in vitro.41 A similar situation has also
been reported with BMP-2-adsorbed fibroin scaffolds, hy-
pothesized to degrade at a similar rate, in which the growth
factor loaded inside the scaffold retained activity for a
longer period.8 Thus, it has been suggested that materials
exhibiting an higher retention of BMPs yield increased os-
teoinductive activity and are therefore more interesting for
future clinical applications.42,43
In our contribution, the amounts of BMP-2 loaded into
the fibroin particles (5 and 12.5 mg) were similar to the
values reported in the literature to achieve ectopic bone
formation in rats with BMP-2, using other delivery sys-
tems.40,44,45 Whether the particulate system could be used
in vivo in combinations with hydrogels or scaffolds, as part
of more complex three-dimensional tissue engineering
constructs, remains a question to be explored in future
studies. The feasibility of the use of fibroin to heal bone
fractures has been demonstrated in previous works.8,10,46
One possibility could be the use of the fibroin microparticles
as part of injectable systems or loaded into scaffolds to
achieve a delayed release of BMP-2, as was explored for
other types of materials.47
The fibroin particles have clearly shown to be able to de-
liver BMP-2 in a sustained way, allowing the formation of
new bone in rodents, and may thus constitute a promising
delivery system of BMPs for future bone tissue engineering
clinical trials.
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